MSH6 and Lynch syndrome: The Lynch syndrome cases identified by the Manchester approach but not strategy 2 were mainly path_MSH6 cases (5/7) who had a lower risk of colorectal cancer than path_MLH1 and path_MSH2 cases [33,34], and therefore they and their relatives already benefit less in absolute terms from surveillance.